Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1506 - Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib


09 Oct 2016


Poster display


Victoria Neiman


Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373


V. Neiman1, D. Keizman2, D. Sarid3, J. Lee4, A. Sella5, M. Gottfried2, H. Hammers6, M. Eisenberger6, M. Carducci6, V. Sinibaldi6, E. Rosenbaum1, A. Peer7, A. Neumann7, W. Mermershtain8, K.R. Rouvinov8, R. Berger9, I. Yildiz10

Author affiliations

  • 1 Clinical Oncology, Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, 49100 - Petach Tikva/IL
  • 2 Oncology, Meir Medical Center, Kfar Saba/IL
  • 3 Oncology, Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv/IL
  • 4 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 5 Oncology, Asaf Harofeh Medical Center, Zerifin/IL
  • 6 Oncology, Johns Hopkins Hospital, 21231 - Baltimore/US
  • 7 Oncology, Rambam Health Care Center, Haifa/IL
  • 8 Oncology, Soroka University Medical Center, 84101 - Beer Sheva/IL
  • 9 Oncology, Chaim Sheba Medical Center, Ramat Gan/IL
  • 10 Oncology, Ataturk Training and Research Hospital,Izmir Katip Celebi University, Izmir/TR


Abstract 1506


Sunitinib is a standard treatment for metastatic clear cell renal cell carcinoma (mccRCC). Data on its activity in the rare variant of metastatic chromophobe RCC (mchRCC), is limited. We aimed to analyze the activity of sunitinib in a relatively large and homogenous international cohort of mchRCC patients, in terms of outcome and comparison to mccRCC.


Records from mchRCC patients treated with first line sunitinb in 10 centers across 4 countries were retrospectively reviewed. Univariate and multivariate analyses of association between clinicopathologic factors and outcome were performed. Subsequently, mchRCC pts were individually matched to mccRCC pts. We compared the clinical benefit rate (CBR), progression free survival (PFS), and overall survival (OS) between the groups.


Between 2004-2014, 36 patients (median age 64, 47% male) with mchRCC were treated with first line sunitinib. 78% achieved a clinical benefit (partial response + stable disease). Median progression free survival (PFS) and overall survival (OS) were 10 and 26 months, respectively. Factors associated with PFS were the HENG risk (HR 3.3, p = 0.03) and pre-treatment neutrophil to lymphocyte ratio (NLR) >3 (HR 0.63, p = 0.02). Factors associated with OS were the HENG risk (HR 4.1, p = 0.04), liver metastases (HR 3.8, p = 0.03), and pre-treatment NLR 


In metastatic chromophobe renal cell carcinoma, sunitinib therapy may be associated with similar outcome and toxicities as in metastatic clear cell renal cell carcinoma. The HENG risk and pre-treatment NLR may be associated with PFS and OS.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings